Gene Therapy Approach Targets Huntington's Disease Progression

Latus Bio Inc. has published research in Nature Communications on a gene therapy strategy, LTS-201, aimed at slowing Huntington's disease progression by reducing the MSH3 DNA repair protein. Preclinical results in nonhuman primates showed a significant reduction in MSH3 messenger RNA levels. This represents a novel therapeutic avenue for the currently untreatable inherited neurological disorder.